Search Results - "VAN GLABBEKE, M. M"

Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials by Whelan, J.S., Jinks, R.C., McTiernan, A., Sydes, M.R., Hook, J.M., Trani, L., Uscinska, B., Bramwell, V., Lewis, I.J., Nooij, M.A., van Glabbeke, M., Grimer, R.J., Hogendoorn, P.C.W., Taminiau, A.H.M., Gelderblom, H.

“…Neoadjuvant chemotherapy improves outcome in osteosarcoma. Determination of optimum regimens for survival, toxicity and prognostic factors requires randomised…”
Get full text

Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) by Bernier, Jacques, Cooper, Jay S., Pajak, T. F., van Glabbeke, M., Bourhis, J., Forastiere, Arlene, Ozsahin, Esat Mahmut, Jacobs, John R., Jassem, J., Ang, Kie-Kian, Lefèbvre, J. L.

“…Background. In 2004, level I evidence was established for the postoperative adjuvant treatment of patients with selected high‐risk locally advanced head and…”
Get full text

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study by Kroep, J.R., Ouali, M., Gelderblom, H., Le Cesne, A., Dekker, T.J.A., Van Glabbeke, M., Hogendoorn, P.C.W., Hohenberger, P.

“…Background: The role of chemotherapy in advanced malignant peripheral nerve sheath tumor (MPNST) is unclear. Patients and methods: Chemotherapy-naive soft…”
Get full text

Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group by Schlemmer, M, Reichardt, P, Verweij, J, Hartmann, J.T, Judson, I, Thyss, A, Hogendoorn, P.C.W, Marreaud, S, Glabbeke, M. Van, Blay, J.Y

“…Abstract Rationale Angiosarcomas of soft tissue represent a heterogenous group of rare sarcomas with specific clinical behaviour and risk factors. Paclitaxel…”
Get full text

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas by Van Glabbeke, M, Verweij, J, Judson, I, Nielsen, O.S

“…We have estimated progression-free rates (PFR) for various groups of soft-tissue sarcoma patients from our clinical trials database, to provide reference…”
Get full text

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial by LE CESNE, A, BLAY, J. Y, COLLIN, F, JIMENO, J, DI PAOLA, E, VAN GLABBEKE, M, NIELSEN, O. S, JUDSON, I, VAN OOSTEROM, A, VERWEIJ, J, RADFORD, J, LORIGAN, P, RODENHUIS, S, RAY-COQUARD, I, BONVALOT, S

“…This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m(2)…”
Get full text

Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups by Bartelink, H, Roelofsen, F, Eschwege, F, Rougier, P, Bosset, J F, Gonzalez, D G, Peiffert, D, van Glabbeke, M, Pierart, M

“…To investigate the potential gain of the concomitant use of radiotherapy and chemotherapy in improving local control and reducing the need for colostomy, a…”
Get more information

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study by LORIGAN, Paul, VERWEIJ, Jaap, BLAY, Jean-Yves, PAPAI, Zsuzsa, RODENHUIS, Sjoerd, LE CESNE, Axel, LEAHY, Michael G, RADFORD, John A, VAN GLABBEKE, Martine M, KIRKPATRICK, Anne, HOGENDOORN, Pancras C. W

“…Single-agent doxorubicin remains the standard treatment for advanced soft tissue sarcomas. Combining doxorubicin with standard-dose ifosfamide has not been…”
Get full text

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study by VAN GLABBEKE, M, VAN OOSTEROM, A. T, OOSTERHUIS, J. W, MOURIDSEN, H, CROWTHER, D, SOMERS, R, VERWEIJ, J, SANTORO, A, BUESA, J, TURSZ, T

“…A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven clinical trials investigating the use of doxorubicin- or…”
Get full text

RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma by Therasse, P., Le Cesne, A., Van Glabbeke, M., Verweij, J., Judson, I.

“…The present study was set up just after the publication of the response evaluation criteria in solid tumors (RECIST) as a prospective validation exercise in…”
Get full text

Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group by LE CESNE, A, JUDSON, I, VAN OOSTEROM, A, TURSZ, T, VERWEIJ, J, CROWTHER, D, RODENHUIS, S, KEIZER, H. J, VAN HOESEL, Q, BLAY, J. Y, FRISCH, J, VAN GLABBEKE, M, HERMANS, C

“…This randomized multicenter study was designed to compare the activity of a high-dose doxorubicin-containing chemotherapy regimen with a conventional…”
Get full text

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients by Eisenhauer, E. A., Vermorken, J. B., van Glabbeke, M.

“…Background The probability of response to chemotherapy following platinum based treatment in ovarian cancer has usually been related to the ‘platinum-free…”
Get full text

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group by Tirelli, U, Errante, D, Van Glabbeke, M, Teodorovic, I, Kluin-Nelemans, J C, Thomas, J, Bron, D, Rosti, G, Somers, R, Zagonel, V, Noordijk, E M

“…We report the results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group, which compared a…”
Get more information

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group by Švancárová, L, Blay, J.Y, Judson, I.R, van Hoesel, Q.G.C.M, van Oosterom, A.T, le Cesne, A, Keizer, H.J, Hermans, C, van Glabbeke, M, Verweij, J, Hogendoorn, P.C.W, Nielsen, O.S

“…Gemcitabine (2′-deoxy-2′-difluorocytidine monohydrochloride) at a dose of 1250 mg/m2 was given as a 30-min intravenous (i.v.) infusion on days 1 and 8 in a…”
Get full text

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group by Nielsen, O.S., Judson, I., van Hoesel, Q., le Cesne, A., Keizer, H.J., Blay, J.Y., van Oosterom, A., Radford, J.A., Svancárová, L., Krzemienlecki, K., Hermans, C., van Glabbeke, M., Oosterhuis, J.W., Verweij, J.

“…In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m 2 repeated every 4 weeks with adequate…”
Get full text

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer by Piccart, M J, Klijn, J, Paridaens, R, Nooij, M, Mauriac, L, Coleman, R, Bontenbal, M, Awada, A, Selleslags, J, Van Vreckem, A, Van Glabbeke, M

“…To confirm the efficacy of docetaxel in patients with breast cancer previously treated with one chemotherapy regimen for advanced or metastatic disease and to…”
Get more information

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years by Penel, N., Van Glabbeke, M., Marreaud, S., Ouali, M., Blay, J.Y., Hohenberger, P.

“…The prognosis of advanced soft tissue sarcoma remains poor. Many phase II trials investigating new regimens have been published in the last 10 years. Full…”
Get full text

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group by Debiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., Dimitrijevic, S., Sciot, R., Stul, M., Vranck, H., Scurr, M., Hagemeijer, A., Van Glabbeke, M., van Oosterom, A.T.

“…Previous studies have shown that activating mutations of c-KIT/ PDGFRA, potential therapeutic targets for imatinib mesylate, are implicated in the…”
Get full text

Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study by BRAMWELL, V. H. C, STEWARD, W. P, USCINSKA, B, KIRKPATRICK, A. L, MACHIN, D, VAN GLABBEKE, M. M, NOOIJ, M, WHELAN, J, CRAFT, A. W, GRIMER, R. J, TAMINAU, A. H. M, CANNON, S. R, MALCOLM, A. J, HOGENDOORN, P. C. W

“…Studies involving small case series have suggested that malignant fibrous histiocytoma of bone (MFH-B) is a chemosensitive tumor and that chemotherapy may…”
Get full text

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols by de Jong, Daphne, Koster, Ad, Hagenbeek, Anton, Raemaekers, John, Veldhuizen, Dennis, Heisterkamp, Sabien, de Boer, Jan Paul, van Glabbeke, Martine

“…1 Dept. of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands 2 Dept. of Internal Medicine, Vie Curi Medical Center, Venlo, the…”
Get full text